RT Journal Article
SR Electronic
T1 Inhaled corticosteroids for the treatment of COVID-19
JF European Respiratory Review
JO EUROPEAN RESPIRATORY REVIEW
FD European Respiratory Society
SP 220099
DO 10.1183/16000617.0099-2022
VO 31
IS 166
A1 Bafadhel, Mona
A1 Faner, Rosa
A1 Taillé, Camille
A1 Russell, Richard E.K.
A1 Welte, Tobias
A1 Barnes, Peter J.
A1 Agustí, Alvar
YR 2022
UL https://publications.ersnet.org//content/31/166/220099.abstract
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms.Treatments are urgently needed to improve outcomes for patients with coronavirus disease 2019 (COVID-19) infection. This review summarises the evidence for the potential protective role of inhaled corticosteroids in preventing severe COVID-19 https://bit.ly/3yCAvfn